Company / Financials
Travere Therapeutics, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$490.7M
FY2025 · +110.5% YoY
Net Income
-$25.5M
FY2025 · +92.1% YoY
Profit Margin
-5.2%
FY2025 · net income / revenue
ROE
-22.3%
FY2025 · return on equity
Total Assets
$605.2M
FY2025
Total Debt
-
FY2025
Equity
$114.8M
FY2025
ROA
-4.2%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$490.7M+110.5% YoYNet Income HistoryProfit after all expenses and taxes-$25.5M+92.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$10.3M+33.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$62.8M+80.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$337.2M+27.7% YoYR&D Expense HistoryResearch and development spending$206.0M-5.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$11.3MIncome Tax HistoryTotal income tax expense$988.0K+723.3% YoYEPS (Basic) HistoryBasic earnings per share-$1.50+65.7% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.50+65.7% YoY